Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome
- 1 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 6 (6), 1308-1315
- https://doi.org/10.2215/cjn.09421010
Abstract
Background and objectives Prednisone and calcineurin inhibitors are the mainstay therapy of idiopathic nephrotic syndrome (INS) in children. However, drug dependence and toxicity associated with protracted use are common. Case series suggest that the anti-CD20 monoclonal antibody rituximab (RTX) may maintain disease remission. Design, setting, participants, & measurements This open-label randomized controlled trial was powered to show that a strategy based on RTX and lower doses of prednisone and calcineurin inhibitors was noninferior to standard doses of these agents in maintaining 3-month proteinuria as low as baseline or up to 1 g/d greater (noninferiority margin). Participants were stratified by the presence of toxicity to prednisone/calcineurin inhibitors and centrally assigned to add RTX (Mabthera, 375 mg/m2 intravenously) to lower doses of standard agents or to continue with current therapy alone. The risk of relapse was a secondary outcome. Results Fifty-four children (mean age 11 ± 4 years) with INS dependent on prednisone and calcineurin inhibitors for >12 months were randomized. Three-month proteinuria was 70% lower in the RTX arm (95% confidence interval 35% to 86%) as compared with standard therapy arm (intention-to-treat); relapse rates were 18.5% (intervention) and 48.1% (standard arm) (P = 0.029). Probabilities of being drug-free at 3 months were 62.9% and 3.7%, respectively (P < 0.001); 50% of RTX cases were in stable remission without drugs after 9 months. Conclusions Rituximab and lower doses of prednisone and calcineurin inhibitors are noninferior to standard therapy in maintaining short-term remission in children with INS dependent on both drugs and allow their temporary withdrawal.This publication has 39 references indexed in Scilit:
- Serum Creatinine Levels Are Significantly Influenced by Renal Size in the Normal Pediatric PopulationClinical Journal of the American Society of Nephrology, 2011
- Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndromeClinical and Experimental Immunology, 2010
- Familial forms of nephrotic syndromePediatric Nephrology, 2010
- Rituximab in refractory nephrotic syndromePediatric Nephrology, 2009
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabThe New England Journal of Medicine, 2009
- Fatal pulmonary fibrosis after rituximab administrationPediatric Nephrology, 2009
- Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental GlomerulosclerosisClinical Journal of the American Society of Nephrology, 2009
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 casesPediatric Nephrology, 2008
- Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical FeaturesAmerican Journal of Neuroradiology, 2008
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnnals Of The Rheumatic Diseases, 2007